Rising anti-Chinese sentiments and India’s search for alternative sources of bulk drugs have come as booster dose for sick public sector enterprises like Hindustan Antibiotics (HAL).
The firm is charting a turnaround plan by beginning the manufacturing of key bulk drugs that the government has identified under a production-linked incentive (PLI) scheme.
Speaking to Business Standard, Nirja Saraf, managing director of HAL, said: “We have requested the government to review the decision to go for a strategic sale of HAL.”
The PSU is planning to invest Rs 20 crore (requirement for the newly announced PLI scheme) to augment its production